Soheil Meshinchi

The paper identifies enhancer hypermethylation as a feature of C/G AML linked to venetoclax response and shows DNMT3B inhibition enhances treatment efficacy.

This paper identifies an EZH2-driven immune evasion phenotype in FUS::ERG AML that is reversible with tazemetostat, offering a potential targeted therapy for high-risk acute leukemia.

This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.

This study shows that the developmental stage of hematopoietic stem cells influences leukemic transformation, lineage hierarchy, and therapy response in pediatric leukemia.

This study shows that AML relapse after BET inhibitor or chemotherapy involves Myc-Ras transcriptional changes, highlighting transcriptional plasticity in relapsed leukemias.

This paper introduces scrHLA-typing, a method to quantify HLA transcripts in single cells using long-read sequencing, showing its ability to detect allele-specific expression in post-transplant relapse samples.

This study examines lymphocyte dynamics during chemotherapy in pediatric AML, finding preserved or increased lymphocytes alongside blast reduction, suggesting a potential window for BiTE therapy.

This study shows TP53 mutations cause resistance to revumenib in AML and suggests combining MCL-1 inhibitors with menin inhibitors could be effective.

This study shows KMT2A oncoproteins drive lineage-switching and epigenetic resistance in leukemia by dynamically binding chromatin and persisting as ENL-marked lesions despite therapy.

The paper develops an automated CUT&Tag method to profile chromatin occupancy of KMT2A fusion proteins in leukemia samples, revealing epigenomic heterogeneity and therapeutic sensitivity.

RNAIndel identifies somatic coding indels in tumor RNA-Seq data with high sensitivity and low false positives, outperforming existing methods.